DCE-MRI for evaluation of response to gefitinib: comparison of two treatment regimens in a breast cancer model
Aliu S, Wilmes L, Li K, Hann B, Wang D, Moasser M, Hylton N
University of California San Francisco
Dynamic contrast enhanced (DCE) MRI was used to study breast tumor response to two dosing regimens of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib. Differences in tumor T10, endothelial transfer constant (Kps) and growth response were seen between the two groups at early and late treatment time points. The 2-day pulse group showed a significant transient decrease in tumor T10 and Kps accompanied by reduced volume shortly after the dosing was completed. For all groups, a correlation between tumor Kps and percent change in tumor size was observed.